Starpharma expands drug delivery program with AstraZeneca

THE ROADHOUSE PHARMACY: Starpharma Holdings (ASX: SPL) has signed a second, expanded agreement with AstraZeneca in the field of cancer medicine using Starpharma’s proprietary DEP™ dendrimer drug delivery technology.

The agreement follows on from an evaluation by AstraZeneca which began in September 2012 of Starpharma’s delivery technology.

The new agreement will see the application of Starpharma’s technology to a cancer drug, from AstraZeneca’s pipeline.

Under the new agreement, AstraZeneca will provide funding for a preclinical stage cancer research program to be conducted jointly.

Starpharma uses its DEP™ technology to improve the performance of pharmaceuticals.

Dendrimer-enhanced versions of drugs have been found to be superior to the unmodified drugs in pre-clinical studies, often having improved efficacy and fewer side effects or toxicities.

Email: investor.relations@starpharma.com

Website: www.starpharma.com

New version ReCell launched in UK and Europe

THE ROADHOUSE PHARMACY: Regenerative medicine company Avita Medical (ASX: AVH) has developed and released to market a new version of ReCell® ‘Spray‐on Skin®’ that no longer requires refrigeration.

The company claims this greatly improves the commercial and practical benefits to clinicians.

The new version of ReCell has been cleared for use and is starting to be sold in the United Kingdom and Europe.

Avita Medical indicated it is also in the process of submitting an application for review to the Therapeutic Goods Administration (TGA) in Australia, where the product must currently be refrigerated.

The company said the regulatory approval and commercial launch of the non‐refrigerated ReCell is part of its ongoing commercialisation strategy for its ReCell ‘Spray‐on Skin’ technology, which includes improvements in ease‐of‐use to enhance the product’s value proposition to the clinical market.

Avita Medical believes the elimination of the inconvenience associated with temperature‐controlled product would be valuable in generating ReCell sales.

“Until now, ReCell has required refrigeration, which often meant it was not immediately on hand in the operating theatre,” Avita Medical interim chief executive officer Tim Rooney said in the company’s announcement to the Australian Securities Exchange.

“The fact that this product can be stored on the shelf until use is a valuable element in providing a more convenient and attractive product, particularly in situations where time is of crucial importance.”

“Our aim is to develop, trial, register and sell exceptional tools and products that provide benefits to patients and integrate well into clinical practice.

“I believe this is a positive step in our marketing strategy to increase ReCell sales.”

Website: www.avitamedical.com

Sino Gas & Energy Holdings kicks off 2014 field work

Sino Gas & Energy Holdings kicks off 2014 field work

THE ROADHOUSE BOSWER: Sino Gas & Energy Holdings (ASX: SEH) is progressing its field operations for 2014 on the company’s Production Sharing Contracts (PSCs) in the Ordos Basin, China.

The company has 285 kilometres of seismic acquisition completed in January being interpreted by third-party contractors, which it expects to be completed in Q2 2014.

Sino explained the seismic completes the grid required for the first round of
Chinese Reserve Report (CRR) submissions across both PSCs.

A total of eight rigs have been mobilised and commenced drilling towards total depth.

The wells are part of a 14 well exploration program Sino has designed to obtain drilling data required for the first round CRR submissions, which are anticipated to be completed in the second half of the calendar year.

The company plans to drill to 59 wells in 2014, the majority of which are expected to be tied into the pilot pipeline production program.

Testing teams arrived onsite in March and commenced frac testing in early
April.

Currently almost forty layers are expected to be tested as a part of the exploration program designed to complete the requirements for CRR submission.

Sino Gas has planned its first horizontal well to be tested in May to allow fraccing equipment to be fine-tuned initially on vertical wells after being held in storage during the winter break in operations.

Engineering for the surface gathering facilities is progressing on the first central gathering station, with additional equipment expected to be delivered early Q2 to complete the facility while the third-party pipeline spur is approaching completion.

“It is pleasing that after a successful 2013 work program delivered significant reserves and resources maturation that the field operations have commenced with the aim of completing first round CRR submission across both PSCs and the commencement of pilot pipeline production in 2014,” Sino Gas managing director and CEO Robert Bearden said in the company’s announcement to the Australian Securities Exchange.

Website: www.sinogasenergy.com

New study shows improved outcomes

THE ROADHOUSE PHARMACY: AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central aortic blood pressures and arterial stiffness noninvasively, has announced that the results of a clinical study which examined treatment of heart failure patients guided by central blood pressure waveform analysis, as measured by SphygmoCor, has been published in the Journal of the American Heart Association.

AtCor Medical said the study found that patients who received medical therapy for heart failure which was guided by central augmentation index (Alx) were able to be treated more effectively with current standard medications, compared to when traditional methods using brachial cuff (arm) blood pressure were applied.
 
Using the central augmentation index to guide therapy resulted in a clinically significant improvement in exercise capacity (peak oxygen consumption), with no increased risk of hypotension or loss of kidney function.

The increase in exercise capacity was on par with the results of alternative heart failure treatments such as cardiac resynchronization therapy (implanting a pacemaker).

AtCor Medical indicated that this was the first randomised controlled trial to manage therapy using central aortic pressures in heart failure patients and was conducted at the Mayo Clinic and the University of Arizona Medical Centre.

The trial considered data from 50 subjects and assessed them over a 6-month period.
 
Adjustments to the patient’s medication were made at monthly intervals.

The primary study endpoint was improved exercise capacity, demonstrating reduced risk and improved quality of life for heart failure patients.

Central AIx is a key measure of arterial stiffness and pressure after load on the heart.

“Heart failure is a chronic, high-cost condition that has the attention of payers, physicians and patients alike,” AtCor Medical CEO Duncan Ross said in the company’s announcement to the Australian Securities Exchange.

“This trial shows that physicians can manage patients with chronic heart failure more effectively using the central pressure waveform.

“The study also demonstrates the importance of measuring central aortic blood pressures, as measured by a fully featured waveform, to fully understand what is happening in the arterial system and at its intersection with the heart.

“AtCor’s ultimate goal is to have these central pressure measurements more widely adopted in pre-hypertension and early-stage hypertensive patients, allowing earlier intervention and preventing advancement to this stage of disease.”

Regeneus partners with US specialist manufacturer

THE ROADHOUSE PHARMACY: Regeneus (ASX: RGS) has partnered with US specialist veterinary vaccine manufacturer, Hennessy Research, for the production of the company’s new autologous canine cancer immunotherapy, Kvax.

This news follows the company’s announcement in November 2013 that it had been given the go ahead from the US Centre for Veterinary Biologics to commercialise the canine cancer immunotherapy in the United States.

Kansas City based Hennessy Research specialises in the manufacture of vaccines for animals and will produce Kvax for the upcoming marketing trials in the US.

“Hennessy Research has a very strong reputation in the animal vaccine field and an impeccable track record with the US veterinary regulators,” Regeneus head of the veterinary business unit Duncan Thomson said in the company’s announcement to the Australian Securities Exchange.

“The partnership with Hennessy Research allows us entry into the world’s biggest veterinary market, the US market.”

Regeneus explained Kvax immunotherapy uses the removal of a tumour or biopsy from the patient as source material to produce a personalised vaccine.

Pieces of tumour will be shipped from US veterinary clinics to Hennessy for manufacture of vaccines.

The vaccines will be shipped back to the veterinary clinics for injection into the patients.
 
The vaccine stimulates the patient’s immune system to see the cancer cells as foreign and helps prevent further growth of the tumour as well as development of new tumours.

The technology was developed by Professor Ross Davey and Dr Chris Weir at the Bill Walsh Translational Cancer Research Laboratory, which is part of the Kolling Institute of Medical Research at the Royal North Shore Hospital in Sydney.

“This is a new type of cancer treatment that has a significant commercial opportunity,” Hennessy founder and CEO Kristine Hennessy said.

“Our company is excited about being involved in the roll-out of the technology in the US veterinary market.”

Regeneus said its next step following the establishment of a manufacturing site in the United States, will be to begin a marketing trial in dogs with key opinion leaders in the United States.

According to the US National Canine Cancer Foundation, cancer accounts for almost half of the deaths of pets over 10 years of age, which is roughly the same rate as humans.

Website: www.regeneus.com.au

This Week in the Roadhouse Pharmacy

THE ROADHOUSE PHARMACY: There’s a great deal of interest in the Bio-tech sector at the moment, so we have opened our own Pharmacy to keep our readers up to speed.

Regeneus partners with US specialist manufacturer

Regeneus (ASX: RGS) has partnered with US specialist veterinary vaccine manufacturer, Hennessy Research, for the production of the company’s new autologous canine cancer immunotherapy, Kvax. READ MORE…

New Study shows improved outcomes

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central aortic blood pressures and arterial stiffness noninvasively, has announced that the results of a clinical study which examined treatment of heart failure patients guided by central blood pressure waveform analysis, as measured by SphygmoCor, has been published in the Journal of the American Heart Association. READ MORE…

ASDM licences synthetic bone substitute with University of Sydney

Orthopaedic devices manufacturer, Advanced Surgical Design and Manufacture Limited (ASDM) (ASX: AMT) has executed a global Licence Agreement with The University of Sydney relating to a composite biocompatible ceramic material known as Sr-HT-Gahnite. READ MORE…

Antisense releases Toxicology Study findings

Antisense Therapeutics (ASX: ANP) released results from a chronic toxicity study in monkeys, which it says indicate ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose). READ MORE…

Nanosonics signs strategic partnership

Nanosonics Limited (ASX: NAN) has entered into a strategic partnership with Miele Professional for the distribution of trophon®EPR in Germany. READ MORE…

Raising funds across the Boards

THE FUND RAISER: There’s been some happy explorers boosting their coffers this week.

$5 Million to advance Brazilian iron ore projects

Centaurus Metals (ASX: CTM) has raised $5 million through a share placement to existing and new investors, underpinned by its cornerstone shareholders Atlas Iron (ASX: AGO) Liberty Metals & Mining Holdings.

Centaurus said it also intends to undertake a Share Purchase Plan on the same terms to enable existing shareholders to participate in this capital raising.

The SPP will raise up to a further $2 million.

The funds raised will enable Centaurus to maintain the current development momentum at its flagship Jambreiro iron ore project in south‐east Brazil while it completes a main debt and equity funding package to facilitate the project’s development.

$1.9m Government grant milestone payments

Carnegie Wave Energy (ASX: CWE) has completed the final foundation milestone and a progress milestone for the onshore plant component of the company’s Perth Wave Energy project with the receipt of $739,862 from the Western Australian State Government and just under $1.17 million in payment claims submitted to the Australian Government.

Carnegie received $739,862 for completion of two milestones from the Western Australian State Government under its LEED Grant.

The milestone payments were awarded for Carnegie’s progress on the onshore plant and the completion of the foundations for the Perth project.

Carnegie has submitted milestone payment claims worth $1,165,921 for the completion of these milestones to the Australian Government under its grant from the Australian Renewable
Energy Agency (ARENA) Emerging Renewables Program.

Placement and Rights Issue

Horseshoe Metals (ASX: HOR) announced plans for a placement and rights issue to raise up to $2.05 million to continue its targeted exploration at the company’s copper-gold projects in the Peak Hill Minerals Field of Western Australia.

The company has entered into placement and subscription agreements with Michael Fotios, a director of the company, and/or his nominees (Placees) to raise $630,000 via the issue of just over 20.6 million shares at approx. 3.05 cents per share, a premium to current share price.

The Placees may also elect to subscribe for an additional approx. 13.76 million shares at 2 cents per share to raise $275,238.

Horseshoe Metals undertake a 2 for 3 non-renounceable rights issue at an issue price of 2 cents per share to raise approx. $1.15 million.

Funds raised will be used to drill high-priority targets at the Kumarina project and follow-up exploration at the nearby Horseshoe Lights project.

Savannah discovery widens Panoramic’s outlook

THE INSIDE STORY: Panoramic Resources (ASX: PAN) has discovered a new zone of nickel mineralisation, which could significantly extended the current mine life of Savannah.

Nickel enjoyed a buoyant beginning to 2014, thanks to the Indonesian Government’s ban on the export of nickel laterite ores.

Before the ban Indonesia was the world’s biggest exporter of nickel and the main supplier of low-grade nickel laterite ores to China’s nickel pig iron industry.

“I don’t want to comment on Indonesian politics but I do understand the rationale for the decision they have made,” Panoramic Resources Managing Director Peter Harold told The Resources Roadhouse.

“I will, however, say we are very happy to see the impact that decision is having.

“Combined with the weaker currency there has been a significant improvement, in Australian dollar terms, in the nickel price.

“That means we are making good money now from our existing operations as our margins have recovered.”

Panoramic Resources operates two 100%-owned underground nickel sulphide mines in Western Australia, the Savannah project in East Kimberley and the Lanfranchi project near Kambalda.
 
The company produced 19,561 tonnes of contained nickel in FY2013 and recently increased its guidance, forecasting to produce between 21,500 and 22,000 tonnes in FY2014.

One troubling aspect of any mine is that every tonne of ore produced moves it closer to the end of its life.

Panoramic could have recently discovered the elixir of mine life in the form of the Savannah North mineralised zone.

Drill hole KUD1525 was the first of a new drill program Panoramic designed to explore for the faulted continuation of the Savannah Intrusion to the north of the existing mine.

As far as first holes go, it couldn’t have been better with initial results returning assays of:

89.3 metres at 1.6% nickel, 0.76% copper, 0.12% cobalt from 704.9 metres, including:

13.2m at 2.1% nickel, 0.72% copper, 0.15% cobalt from 741.8m; and

17m at 2.28% nickel, 1.16% copper, 0.17% cobalt from 777m.

 

“The Savannah story is very much now about maintaining record production levels, keeping costs down, the recent discovery at Savannah North and its potential in regards to our ability to increase reserves and extend mine life, given that we are now down to three years based on the current reserve,” Harold said.

“First and foremost Savannah North is a wonderful discovery by our geological team, led by John Hicks, who had the foresight and the knowledge to look in that area.

“He really had nothing more than a blank sheet of paper, yet was able to develop a theory of the potential existence of a fold, which if correct would mean the orebody could continue to the north.

“He wasn’t basing his assumptions on any particular EM targets, aeromagnetic surveys or such; it was based purely on his intimate knowledge of the ore body above the 900 fault, the drilling below the 900 Fault and what may have happened as a result of a geological event.

“It was really good geological detective work to anticipate a possible continuation in what was a totally untested area.”

The Savannah North discovery has to be one of the better examples in recent times of the courage and faith required for successful exploration.

Courage initially from Hicks to approach the Board with what he considered to be the best option for him to follow; faith displayed by the company in Hicks’ knowledge of the geology to support his assumptions; and both by very supportive brokers, a significant new investor in Zeta Resources and the marketplace, which rallied to raise the money giving Panoramic the confidence to carry out an aggressive exploration program.

“We raised $15 million, in a very tough market, for nickel exploration,” Harold said.

Subsequent to the discovery, KUD1525 intersected a second zone of mineralisation of: 8.7m at 1.23% nickel, 0.87% copper and 0.09% cobalt from 882.5m, which was interpreted to be mineralisation caught up within the 900 Fault zone, lying below the Savannah North discovery.

“We are definitely onto something and down-hole EM surveying of KUD1525 identified targets to follow-up, which has provided much confidence as well as the impetus to get in there and do some serious drilling,” Harold said.

“We have one underground rig and two surface rigs drilling focusing on the area where that EM target was identified and where we encountered mineralisation previously, to test the entire structure in order to determine just how big it may be.

“The sooner we convert all that drilling into Resources and Reserves the sooner we can start thinking about mine life extension.”

With everything happening at Savannah, it would be easy to presume Panoramic was concentrating all of its efforts there.

However, there is still a lot of action at the Lanfranchi project where a number of prospective targets have been identified.
 
“From the $15 million we raised last year we determined to spend as much as possible on nickel exploration at both sites,” Harold said.

“We budgeted an equal amount of money at Lanfranchi with the intention of extending existing ore bodies, potentially identifying a new mineralised channels.

“There’s been no major discoveries yet, but we are confident, as we know the Kambalda Field has a track record of producing a lot of ore.”

 

Panoramic’s diversity extends beyond the two nickel mines it operates to incorporate other commodities.

The Gidgee gold project near Wiluna in WA, includes the high-grade Wilsons project, while the company also holds a 70% interest in the Mt Henry gold project near Norseman.

“We are in the process of finishing off Feasibility Studies on both these project, both of which we anticipate being completed by around June this year,” Harold said.

“We are keen to get those finished to get a good idea of how those projects look in 2014 dollars from a capital and operating cost perspective.

“We expect one of those projects to look better than the other one in terms of risk and ecomonics i.e. free cash, NPV, and internal rate of return.

“The better project will get front running on development, then the rest is up to the gold price.

“Ultimately we will make decisions on our gold projects that provides the best return for our shareholders.”

Panoramic has also expanded into Platinum Group Metals (PGMs) having purchased the Panton PGM project near the Savannah project and the Thunder Bay North PGM project in Northern Ontario, Canada.

The company has a bullish outlook for platinum and palladium prices in the medium term and is keeping a close eye on South Africa as far as production is concerned given there was a ten% drop in production there of platinum and palladium last year and rumours of Russia’s stockpile of palladium coming to an end.

“PGM demand is growing strongly mostly for catalytic converters in cars and with the car market growing rapidly in Southeast Asia, and recovering American market and Europe this bodes well for PGM demand,” Harold said.

“There seems to be a potential supply and demand imbalance developing with many analysts forecasting higher platinum and palladium prices.

“Our view is that we have a reasonably cheap option on platinum and palladium with our two assets, and like our gold assets, we’re happy to wait and take advantage of improved prices in the future.

Panoramic Resources Limited (ASX: PAN)
…The Short Story

HEAD OFFICE
Level 9
553 Hay Street
Perth   WA   6000

Ph: +61 8 6266 8600
Fax:   +61 8 9421 1008

Email: info@panres.com
Website: www.panoramicresources.com

DIRECTORS and MANAGEMENT
Brian Phillips, Peter Harold, Christopher Langdon, John Rowe

MAJOR SHAREHOLDERS
M&G Investment Ltd 10.7%
HSBC Nominees 12.9%
JPM Nominees 12.6%
Zeta Resources 10.7%

SHARES ON OFFER
322.27 million

MARKET CAPITALISATION
$143.4 million (at 3/4/14)

Miners reject royalty rate rise

THE CONFERENCE CALLER: The Western Australian Government has a looming budget blow out and a pesky panel beating bill to pay.

At the Paydirt Gold Conference in Perth this week WA Department of Mines and Petroleum director-general Richard Sellers gave notice the State Government’s royalty review could be considering a staggered change in gold royalty rates.

The rumour doing the rounds at present is that the review could be looking at doubling the royalty rate from 2.5 per cent to five per cent.

Taking the heat for Mines Minster Bill Marmion, who cancelled his appearance at the conference at the last minute, Sellers told delegates it was unclear whether the joint DMP and Department of State Development task force conducting the review would recommend a multi-tiered gold royalty system, which would acknowledge the differing cost structures and profitability of WA mines.

Sellers did admit, however one of the aims off the review was to keep the royalty system simple – to benefit miners or bureaucrats he didn’t say.

“We know it is a very varied industry where you have some very high-cost producers and then some others that have very high grades and produce at a lower cost,” he said.

“But the difficulty is that if you tried to design a system that catered for that it would get very complex and very hard. My gut feeling is that it will stay a simple process.”

Later in the day a panel session featuring a gaggle of the State’s leading golden egg laying geese, including Kelvyn Eglinton of Newmont Asia Pacific, Bill Beament of Northern Star Resources, Matt Judkins of Deloitte Access Economics, Allan Kelly of Doray Minerals, and Dianmin Chen of Norton Goldfields lined up to express their concerns about the potential hike in royalties.

 

The panel members were representing the Gold Royalties Response Group (GRRG), which was initially formed in 2010 when the possibility of a raise in gold royalties first poked its head above the parapet.

Kelly suggested the idea was a short sighted one by the WA government saying that although it may supply short term benefits in more money being syphoned of gold producers now, it would most probably result in having a detrimental effect on the current group of explorers, ultimately leading to a dearth of gold mining companies in the future.

Beament supported Kelly’s idea, adding that as a company Northern Star currently pays some $15 million per annum into the State’s coffers.

Should the royalty rate double – the math is reasonably simple – that figure rises to $30 million, a figure Beament suggested would be difficult for any busy to absorb into its bottom line.

Eglinton pointed out that, like his company, those represented by the others on the panel, have some big-hitting international mining investment funds on their shareholder register.

These investments, he said, could be in a perilous position if the increase in royalties was introduced as many of these funds could very easily take their cash elsewhere.

Beament stressed this was a real possibility, citing the way international funds had quickly deserted during the Global Financial Crisis and when the price of gold had crashed.

According to a report by Deloitte on the Economic Contribution and Impact Assessment of the WA Gold Sector a hike in the gold royalty could have impacts across the board.

What the Brokers Say

WHAT THE BROKERS SAY: Interesting news and views from across the Resources and Oil & Gas Analyst universe.


website: www.breakawayresearch.com

Carpentaria Exploration (ASX: CAP)

Carpentaria Exploration is primarily a western New South Wales iron ore developer, with 60 per cent ownership of the Hawsons iron ore project, located near Broken Hill.

The project, for which positive economics are indicated, is well served by infrastructure, including power, rail, port and a skilled workforce in Broken Hill.

Carpentaria also has a second string to its bow, actively exploring a package of tenements in New South Wales prospective for intrusion related gold and porphyry related gold/copper deposits.

Carpentaria Exploration (ASX: CAP), along with 40 per cent JV partner Pure Metals, continues to assess development of the Hawsons iron ore project.

The company has recently completed a positive project review, and now is looking to progress through the feasibility phase, for which funding is required.

A key to the project is that it is well served by infrastructure, with potential available capacity for production of up to 8 to 10 million tonnes per annum, thus minimising capex and lead times.

In this, Carpentaria is unique when compared to its peers. There are also potential infrastructure synergies with other projects and companies in the region.

With Pure Metals currently managing the Hawsons project, Carpentaria has the resources to actively explore its package of 100 per cent held intrusion related gold and porphyry related copper/gold projects in central and northern NSW.

These prospective projects are largely located over areas of known mineralisation, however with little modern exploration.

The company has a Board and management team with a proven track record in industry and government that has pro-actively managed projects.

We see short term price appreciation on the back of obtaining a partner to fund the Hawsons DFS and any exploration success on the gold projects, with medium to longer term appreciation to be driven by ongoing advancement of all projects.

Website: www.argonaut.com

Citation Resources (ASX: CTR)

Citation has announced that its Atzam#5 well, onshore Guatemala, has been successfully cased above the first of multiple objectives.

The well is an appraisal of a field that was successfully tested by the Atzam#4 well in 2013.

Atzam#4 is currently producing 170 barrels of oil per day with no water cut and steady pressure (indicating greater deliverability is possible).

The well is choked back until the Operator has a better handle on the impact of a higher production rate on the Estimated Ultimate Recovery (EUR).

The Atzam field may contain as much as 20 million barrels of recoverable oil with additional upside possible from near field exploration (CTR 60 per cent).

Operations have been slower than expected; however, we are now at the pointy end of the process and, given the success at Atzam#4 and oil shows seen already in Atzam#5, we consider the chance of success as high.

Guatemala Re-Cap:

Citation has a 60 per cent interest in the Atzam Oil Field, onshore in Guatemala, through its ownership in the local operating company, Latin American
Resources.

The first well in the recent program, Atzam #4, flowed at >600bopd from a secondary target and has been flowing at a choked back rate of 170bopd.

The current 2P Reserve related to only the Atzam#4 well has been independently estimated at 2.3mmbbl with upside potential for the field as high as 20mmbbl.

Additional potential on the permit is also considered likely with Atzam look-a-likes as well as other play types in which oil production has been proven.

Guatemalan fiscal terms are considered attractive with operating margins of approx. 50 per cent.

Atzam#5 – Layer Upon Layer:

One of the key positives about the Atzam field geology is that there are multiple prospective horizons starting at the C13 level (just below where casing has recently been set).

During the drilling of Atzam#4, many interesting shows were seen but not tested as a standard drilling plan calls for drilling to Total Depth and then testing from the deepest horizon up.

Atzam#4 had issues with the deepest horizons (C18/19 – the primary targets) but fell back to the C17 and achieved a highly successful outcome, albeit that the interesting shallow zones were not tested.

A different approach is being used at Atzam#5 with production testing equipment so that testing can occur on the way down if anything interesting is seen.

The primary targets remain in the deeper horizons; however, we are likely to get significant newsflow on oil shows as well as production testing from other horizons over the next few weeks.

Disclaimer: The above is intended as a guide only. The Roadhouse accepts no responsibility for investments made from this advice, successful or otherwise.

The views, opinions or recommendations of this article do not in any way reflect the views, opinions, recommendations, of The Resources Roadhouse.

The Roadhouse makes no representation or warranty with respect to the accuracy, completeness or currency of the content. The content is for educational purposes only and does not constitute financial advice. Independent advice should be obtained from an Australian financial services licensee before making investment decisions.